Results 231 to 240 of about 48,363 (248)

Proprotein Convertase Subtilisin/Kexin 9 Inhibitors

Journal of Cardiovascular Pharmacology and Therapeutics, 2015
Maria-Corina Serban, Maciej Banach
exaly  

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

Circulation, 2012
Maxime Denis, Ahmed Zaid, Nabil G Seidah
exaly  

Hemmung der Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

CardioVasc, 2013
Valérie Pavlicek, Daniel Urban, Ulrich Laufs   +2 more
openaire   +1 more source

Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials

Journal of the American Heart Association, 2015
Wen Zhang, Liang Zhou, Hao Luo
exaly  

The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice

Journal of Clinical Lipidology, 2019
Robert J Sanchez, Ann Marie Navar-Boggan
exaly  

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

Lancet, The, 2012
exaly  

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors

Circulation, 2016
Karin Leander, Anders Malarstig, Mai-Lis Hellénius   +2 more
exaly  

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

Nicholas A. Marston, Marc S. Sabatine
openaire   +1 more source

Pro-protein convertases of subtilisin/kexin family.

Methods in enzymology, 1995
N G, Seidah, M, Chrétien
openaire   +1 more source

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Lancet, The, 2014
exaly